- Home
- BTBD vs APM Comparison
BTBD vs APM Comparison
Compare BTBD & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | APM |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 8.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTBD | APM |
|---|---|---|
| Price | $1.69 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.0K | ★ 45.7K |
| Earning Date | 11-17-2025 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,038,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.69 |
| 52 Week High | $5.60 | $4.47 |
Technical Indicators
Market Signals| Indicator | BTBD | APM |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 37.70 |
| Support Level | $1.44 | $0.96 |
| Resistance Level | $1.60 | $1.05 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 87.50 | 33.89 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.